Sale!

ANCA-PR3 (Serin Proteinase 3 Antibodies) EIA Test

Original price was: 470 د.إ.Current price is: 420 د.إ.

-11%

The ANCA-PR3 (Serin Proteinase 3 Antibodies) EIA Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to detect the presence of antibodies against Proteinase 3 (PR3) in the blood. Proteinase 3 is an enzyme primarily found in neutrophils, a type of white blood cell. Antibodies against PR3, known as c-ANCA (cytoplasmic Anti-Neutrophil Cytoplasmic Antibodies), are strongly associated with a form of vasculitis called Granulomatosis with Polyangiitis (GPA), formerly known as Wegener’s Granulomatosis. This condition is an autoimmune disorder that causes inflammation of the blood vessels, leading to damage in organs such as the kidneys, lungs, and airways.

The ANCA-PR3 EIA Test employs the enzyme immunoassay (EIA) technique to quantitatively measure PR3-ANCA levels in the serum, providing crucial information for the diagnosis, monitoring, and management of patients suspected of having GPA or other related autoimmune conditions. A positive result may indicate an active or relapsing form of the disease, aiding clinicians in making informed decisions regarding treatment strategies.

DNA Labs UAE offers this test at a cost of 420 AED. Their state-of-the-art facilities ensure accurate and reliable results, making them a preferred choice for patients and healthcare providers seeking comprehensive autoimmune diagnostics. The test is an essential tool in the rheumatology and immunology fields, contributing significantly to the early detection and effective management of autoimmune vasculitis.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

ANCA-PR3 SERIN PROTEINASE 3 ANTIBODIES EIA Test

Test Cost: AED 420.0

Test Name:

ANCA-PR3 SERIN PROTEINASE 3 ANTIBODIES EIA Test

Components:

Corresponds with c-ANCA

Price:

AED 420.0

Sample Condition:

2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Overnight fasting is preferred.

Report Delivery:

Sample Tue / Thu / Sat by 9 am; Report Same day

Method:

Enzyme Immunoassay

Test Type:

Autoimmune disorders

Doctor:

Nephrologist, Physician, Neurologist

Test Department:

Pre Test Information:

No special preparation required

Test Details:

ANCA-PR3 (serine proteinase 3 antibodies) EIA test is a diagnostic test used to detect the presence of anti-neutrophil cytoplasmic antibodies (ANCA) targeting proteinase 3 (PR3) in the blood. This test is primarily used in the diagnosis and monitoring of certain autoimmune diseases, particularly granulomatosis with polyangiitis (GPA) or Wegener’s granulomatosis.

ANCA are autoantibodies that mistakenly attack the body’s own tissues, specifically the neutrophils (a type of white blood cell). PR3 is an enzyme found in the cytoplasmic granules of neutrophils, and when ANCA specifically target PR3, it can lead to inflammation and damage to blood vessels.

The ANCA-PR3 EIA test involves collecting a blood sample from the patient and then analyzing it in the laboratory. The test utilizes an enzyme immunoassay (EIA) technique to detect and quantify the levels of ANCA-PR3 antibodies in the blood. The results are reported as a numerical value, indicating the antibody levels present in the patient’s blood.

A positive result for ANCA-PR3 antibodies can suggest the presence of GPA or other related autoimmune diseases. However, a positive result alone is not sufficient for diagnosis, and further clinical evaluation and additional tests may be required. Conversely, a negative result does not rule out the possibility of these diseases, as ANCA-PR3 antibodies may not always be present or detectable.

Overall, the ANCA-PR3 (serine proteinase 3 antibodies) EIA test is a valuable tool in the diagnosis and management of autoimmune diseases, specifically GPA. It helps healthcare professionals in assessing disease activity, monitoring treatment response, and guiding therapeutic decisions.

Test Name ANCA-PR3 SERIN PROTEINASE 3 ANTIBODIES EIA Test
Components Corresponds with c-ANCA
Price 420.0 AED
Sample Condition 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Overnight fasting is preferred.
Report Delivery SampleTue / Thu / Sat by 9 am; Report Same day
Method Enzyme Immunoassay
Test type Autoimmune disorders
Doctor Nephrologist, Physician, Neurologist
Test Department:
Pre Test Information No special preparation required
Test Details

ANCA-PR3 (serine proteinase 3 antibodies) EIA test is a diagnostic test used to detect the presence of anti-neutrophil cytoplasmic antibodies (ANCA) targeting proteinase 3 (PR3) in the blood. This test is primarily used in the diagnosis and monitoring of certain autoimmune diseases, particularly granulomatosis with polyangiitis (GPA) or Wegener’s granulomatosis.

ANCA are autoantibodies that mistakenly attack the body’s own tissues, specifically the neutrophils (a type of white blood cell). PR3 is an enzyme found in the cytoplasmic granules of neutrophils, and when ANCA specifically target PR3, it can lead to inflammation and damage to blood vessels.

The ANCA-PR3 EIA test involves collecting a blood sample from the patient and then analyzing it in the laboratory. The test utilizes an enzyme immunoassay (EIA) technique to detect and quantify the levels of ANCA-PR3 antibodies in the blood. The results are reported as a numerical value, indicating the antibody levels present in the patient’s blood.

A positive result for ANCA-PR3 antibodies can suggest the presence of GPA or other related autoimmune diseases. However, a positive result alone is not sufficient for diagnosis, and further clinical evaluation and additional tests may be required. Conversely, a negative result does not rule out the possibility of these diseases, as ANCA-PR3 antibodies may not always be present or detectable.

Overall, the ANCA-PR3 (serine proteinase 3 antibodies) EIA test is a valuable tool in the diagnosis and management of autoimmune diseases, specifically GPA. It helps healthcare professionals in assessing disease activity, monitoring treatment response, and guiding therapeutic decisions.